LongVCYTJun 2026
Veracyte, Inc.
Meridian owns Veracyte for durable, volume-driven genomic-testing revenue, an expanding diagnostic menu, and a competitive moat built on more than a decade of proprietary…
VCYT
1 published idea on Veracyte, Inc. across 1 fund — 1 long and 0 short.
Each stock pitch below comes from a fund manager's own investor letter, not a 13F filing, so it carries the reasoning behind the portfolio position on Veracyte: the full investment thesis, the risks the manager flagged, the conviction level and the time horizon. Positions may have changed since the letter was written.
Meridian owns Veracyte for durable, volume-driven genomic-testing revenue, an expanding diagnostic menu, and a competitive moat built on more than a decade of proprietary…